Top Markets
Coin of the day
Bharat Parenterals Limited Bharat Parenterals Limited

Bharat Parenterals Limited

BPLPHARMA
Rank in Stocks #21540
Bharat Parenterals Limited specializes in the development and production of... Bharat Parenterals Limited specializes in the development and production of pharmaceutical formulations, offering a broad spectrum of products. Their diverse portfolio encompasses general-purpose medicines, B-Lactam compounds, cephalosporin-based drugs, anti-retroviral therapies, and veterinary pharmaceuticals. This company was established by Ramesh Desai on September 3, 1992, and operates from its main office situated in Vadodara, India.
Share Price
$15.26
Last synced: 2026-08-21
Market Cap
$105.18M
Change (1 day)
3.28%
Change (1 year)
-4.12%
Country
IN
Trade Bharat Parenterals Limited (BPLPHARMA)

Category

P/E ratio for Bharat Parenterals Limited (BPLPHARMA)
P/E ratio as of 2026 TTM: 0
According to Bharat Parenterals Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Bharat Parenterals Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.